Dara Pharma at GMP‑Pharmatecnica 2026: a successful and strategic participation

On March 24–25, 2026, Dara Pharma took part as an exhibitor at GMP‑Pharmatecnica 2026, held in Wiesbaden, Germany. The event is one of Europe’s leading meetings focused on pharmaceutical manufacturing technology and GMP compliance. Dara Pharma welcomed visitors at stand C8, where professionals showed strong interest in our advanced machinery and turnkey solutions.

GMP‑Pharmatecnica is held alongside the GMP‑PharmaCongress and brings together production, engineering, quality and technical decision‑makers, making it a key platform for networking, knowledge exchange and business development.

High traffic and valuable meetings at stand C8

Throughout the two‑day event, Dara Pharma’s stand remained highly active. Our team held meetings with:

• Pharmaceutical manufacturers and CDMOs
• Biotechnology companies
• Technology partners and existing customers
• Professionals involved in new aseptic processing, filling and formulation projects

Discussions focused on real and ongoing projects, capacity expansion, plant upgrades and compliance with current and future regulatory requirements.

Solutions aligned with industry needs

GMP‑Pharmatecnica 2026 provided an excellent opportunity to reinforce Dara Pharma’s positioning as a global supplier of turnkey pharmaceutical lines, highlighting:

• Flexible and customized designs
• Adaptability to multiple dosage forms
• Full GMP compliance
• A collaborative approach from engineering to after‑sales support

The feedback received was extremely positive and confirmed the market’s demand for reliable, tailored and scalable solutions in an increasingly demanding regulatory environment.

A very positive outcome

Dara Pharma’s participation in GMP‑Pharmatecnica 2026 can be considered a clear success. In addition to strengthening our international visibility, we generated new business opportunities, reinforced existing relationships and confirmed our role as a trusted technology partner for the pharmaceutical industry.

We continue moving forward with a strong commitment to delivering high‑value pharmaceutical technology based on experience, innovation and close customer collaboration.